As previously announced, low dose D-cycloserine has been associated with augmentation of the antidepressant and antisuicidal ...

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said it amended its Investigational New Drug ...

NRx Pharmaceuticals (NRXP) amended its Investigational New Drug filing for NRX-101 to include the use of NRX-101 in association with Transcranial ...

With its policy change, Cigna now joins several other major insurers that cover the device, including Centene, Highmark, Blue Cross Blue Shield, Tricare and Palmetto GBA. More than 86 million adults ...

TORONTO, April 3, 2023 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ: GBNH) ("Greenbrook" or the "Company") today announced that the Company has amended its amended and restated master sales agreement ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted clearance to a transcranial magnetic stimulation device as an adjunctive treatment for major ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. BrainsWay Deep TMS is cleared for use by adolescents and ...

Munich, Germany; Atlanta, Georgia - September 10, 2025 – neurocare group AG (“neurocare” or the “Company”), a leading innovator in personalized mental health and performance, today announced it has ...

NeuroStar Advanced Therapy is a transcranial magnetic stimulation system that uses magnetic fields to induce neural activity in the cerebral cortex. The Food and Drug Administration (FDA) has cleared ...

NeuroStar Advanced Therapy for Mental Health is a transcranial magnetic stimulation system that uses magnetic fields to reignite dormant synapses in the brain. The Food and Drug Administration (FDA) ...

Austin, Texas, United States, December 3rd, 2025, FinanceWire NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said ...